Epigenetic Progeria Reveals DNA Methylation Aging Clock
Background and Challenges
It is now well-established that as we age, DNA methylation accumulates globally in a clock-like manner, activating a "aging clock" throughout the genome. However, it remains unclear whether these changes are merely byproducts or causative factors in disease. Previous studies primarily observed methylation ratios at CpG sites in blood or tissue samples, making it difficult to track how methylation signals stem cell self-renewal or differentiation pathways. In particular, there was a hypothesis that the activity of DNMT3A (DNA methyltransferase 3A) and TET2 (ten-eleven translocation enzyme 2) changes and interacts with histone H3K9me3 (histone 3 lysine 9 trimethylation), but there was no human model to prove this. In this context, the research team discovered a rare disease called "epigenetic progeria syndrome" and found that it accelerates the same methylation patterns as normal aging. Therefore, the core challenge of this study was to use this syndrome to verify whether the aging clock can actually cause tissue dysfunction or is simply a concomitant phenomenon.
Molecular Mechanism of Epigenetic Progeria Revealed
The research team analyzed whole-genome methylation data from progeria patients, focusing on 353 clock genes, and confirmed that CpG islands regulating PROM1 (prominin 1) and SOX2 (SRY-box transcription factor 2) expression were abnormally hypermethylated. This hypermethylation was induced by the overactivation of DNMT3B (DNA methyltransferase 3B), and ChIP-seq results showed that DNMT3B forms a complex that binds to H3K27ac (histone 3 lysine 27 acetylation) and inhibits its activity. Functional experiments showed that when a CRISPR-based DNMT3B inhibition system was applied in patient-induced pluripotent stem cells (iPSCs), the methylation of PROM1 and SOX2 was restored, and the cell's skeletal regeneration ability was more than doubled. In addition, Hi-C analysis revealed that the binding sites of CTCF (CTCF protein) located around the methylated sites were destroyed, leading to instability in the three-dimensional genome structure and inhibition of Wnt/ฮฒ-catenin signaling. This study is the first to demonstrate a mechanism in which excessive DNA methylation simultaneously blocks key transcription factors and signaling pathways in stem cells, thereby hindering tissue regeneration.
Future Implications and Prospects
This discovery suggests that drugs that regulate DNA methylation may become a new strategy for treating age-related diseases, and it has laid the foundation for starting a phase 1 clinical trial by 2028 in conjunction with the ongoing DNMT3B selective inhibitor development project. In addition, by using methylation-based biomarkers to design personalized aging management programs, early diagnosis and preventive interventions can be made possible, which can save billions of dollars in medical costs in a situation where the global elderly population will reach 20% by 2050. The research team is currently conducting a pilot study using CRISPR-Cas9-based epigenetic editing technology to directly repair specific CpG sites, and if successful, it may be possible to commercialize an "epigenetic reverse engine" that promotes tissue regeneration. At the same time, it plans to build an AI (artificial intelligence) platform that precisely models the network in which methylation and histone modification interact, in order to establish a pipeline for rapidly screening new drug candidates. Ultimately, the long-term goal is to improve the quality of human life by not just "stopping" the aging clock, but "resetting" it.
Nature Genetics, Published online: 17 June 2026; doi:10.1038/s41588-026-02632-9With advancing age, clock-like DNA-methylation changes occur across the genome. Whether these changes are passenger events or drive pathology remains to be determined. Here we report a novel epigenetically driven accelerated aging syndrome that connects age-related DNA hypermethylation with stem-cell dysfunction and tissue decline.
As aging progresses, tissue function deteriorates rapidly, leading to high-cost medical problems such as dementia and cardiovascular disease. This study opens the door to directly manipulating DNA methylation, the root cause. Previously, methylation remained a phenomenon that could only be observed, and there was a lack of safe drugs or technologies to reverse it, making clinical application difficult. This study demonstrates that methylation patterns can be accurately reset using a new approach that combines DNMT3B selective inhibitors and CRISPR-Cas9-based epigenetic editing. If this technology is commercialized, it can reduce early-stage clinical trial costs in the 5 trillion won annual market for age-related diseases by 30%, and significantly improve the quality of life for patients through early intervention. In the future, it is expected that an epigenetic reverse engine that can be applied to various tissues will be developed, and it will be expanded into an integrated platform for preventing and treating all diseases related to aging.